USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook
Key Financial Results and Guidance
Fourth Quarter 2024 vs. Fourth Quarter 2023
-
Net sales of
versus$214 million .$221 million -
Net earnings of
as compared to$4.5 million .$16.8 million -
Diluted EPS of
as compared with$0.23 .$0.87 -
Adjusted diluted EPS(1) of
as compared with$0.64 .$0.87 -
Adjusted EBITDA(2) of
versus$25 million .$32 million - USANA Active Customers of 454,000 versus 483,000.
Fiscal Year 2024 vs. Fiscal Year 2023
-
Net sales of
as compared with$855 million .$921 million -
Net earnings of
as compared to$42.0 million .$63.8 million -
Diluted EPS of
versus$2.19 .$3.30 -
Adjusted diluted EPS(1) of
as compared with$2.59 .$3.30 -
Adjusted EBITDA(2) of
versus$110 million .$128 million
Fiscal Year 2025 Outlook
-
Consolidated net sales between
and$920 million , or$1.0 billion 8% -17% growth. -
Net earnings between
and$29 million .$41 million -
Diluted EPS between
and$1.50 .$2.20 -
Adjusted Diluted EPS(1) between
and$2.35 .$3.00 -
Adjusted EBITDA(2) between
and$107 million .$123 million
Q4 2024 Financial Performance
Consolidated Results |
|||
(Net earnings, EPS and EBITDA figures represent
|
Year-over-Year |
Sequentially |
|
Net Sales |
|
- |
+ |
Net Earnings |
|
- |
- |
Diluted EPS |
|
- |
- |
Adjusted Diluted EPS(1) |
|
- |
+ |
Adjusted EBITDA(2) |
|
- |
+ |
“USANA delivered fourth quarter results above our internal expectations, highlighted by
Mr. Brown added, “We also completed our acquisition of Hiya during the quarter, which is a meaningful milestone for USANA and an exciting addition to our business. Hiya is a growing, highly cash generative, direct-to-consumer children’s wellness brand. Hiya has an experienced management team that continues to lead the company and a compelling subscription business model that we believe is positioned to deliver long-term sustainable growth over the next several years. We look forward to supporting Hiya as they build upon their leadership position in the children’s health and wellness market.”
Fiscal Year 2024 vs. Fiscal Year 2023 Financial Performance
Consolidated Results |
||
Net Sales |
|
- |
|
|
- |
|
|
- |
Net Earnings |
|
- |
Diluted EPS |
|
- |
Adjusted Diluted EPS(1) |
|
- |
Adjusted EBITDA(2) |
|
- |
Net earnings, EPS and EBITDA figures represent amounts attributable to USANA |
Mr. Brown continued, “Full year operating results reflected continued, cautious consumer sentiment in many of our key
Q4 2024 Regional Results:
|
|||||
|
Year-
|
Year-over-Year
|
Sequentially |
||
Net Sales |
|
- |
No material FX impact |
+ |
|
USANA Active Customers |
361,000 |
- |
n.a. |
Flat |
Asia Pacific Sub-Regions |
|||||
|
Year-
|
Year-over-Year
|
Sequentially |
||
|
Net Sales |
|
- |
No material FX impact |
+ |
USANA Active |
246,000 |
- |
n.a. |
+ |
|
Customers |
|||||
|
Net Sales |
|
- |
- |
- |
USANA Active |
38,000 |
- |
n.a. |
- |
|
Customers |
|||||
|
Net Sales |
|
- |
- |
+ |
USANA Active |
77,000 |
- |
n.a. |
+ |
|
Customers |
|
|||||
|
Year-
|
Year-over-Year
|
Sequentially |
||
Net Sales |
|
+ |
+ |
+ |
|
USANA Active Customers |
93,000 |
- |
n.a. |
+ |
Hiya contributed approximately
Balance Sheet and Share Repurchase Activity
During the fourth quarter, the Company continued to generate strong operating cash flow and invested approximately
Fiscal Year 2025 Outlook
Mr. Brown continued, “Our growth strategy for the direct sales business in 2025 is centered on our Associate sales force and providing them with the resources needed to generate sustainable active customer growth. This growth strategy includes several key initiatives, including (i) a higher cadence of new product launches and improvements to existing products tailored to local markets, (ii) strategic enhancements and modifications to our Associate incentive offering, which are intended to incent customer growth and improve pay for performance, (iii) strengthening our brand messaging, story, and value proposition, and (iv) accelerating Associate engagement activities in our regions around the world. I’m confident that the successful execution of these initiatives will position us for growth going forward.
“Hiya’s strategic priorities for this year include capitalizing on recent product launches to drive further growth in its direct-to-consumer model, expanding strategic partnerships, and laying the groundwork for channel expansion. We are also working closely with the Hiya team to identify both short- and long-term synergy opportunities. Overall, we remain confident that the Hiya team, which continues to be led by co-founders Darren Litt and Adam Gillman, will deliver strong growth in 2025.”
The Company is providing its outlook for fiscal year 2025, as detailed in the table below:
|
Twelve Months Ended
|
|
Range |
Consolidated net sales |
|
Net Earnings |
|
Diluted EPS |
|
Adjusted diluted EPS(1) |
|
Adjusted EBITDA(2) |
|
Doug Hekking, Chief Financial Officer, said, “We are introducing our consolidated fiscal 2025 outlook, which now includes additional non-GAAP financial metrics to help provide transparency and comparability with prior years following our acquisition of Hiya. Notably, we have included certain transaction-related expenses and integration costs for the Hiya acquisition in our outlook. Furthermore, the purchase price allocation for this acquisition includes a significant amount recognized as intangible assets with material amortization expense that will have a non-cash impact on reported results. Therefore, we are providing estimates for Adjusted diluted EPS(1) and Adjusted EBITDA(2) as part of our outlook to provide enhanced comparability between periods and improved clarity on cash flow generation of the combined enterprise on a year-over-year basis. Additionally, our outlook does not currently reflect the potential increased costs of proposed tariffs on our business as we continue to assess the changing business environment.”
The Company’s outlook reflects:
-
Net sales from the USANA business of
to$775 , which includes an expected unfavorable currency exchange rate impact of approximately$840 million , or -$30 million 4% on net sales; -
Net sales from Hiya of
to$145 , reflecting a year-over-year range of +$160 million 29% to +42% ; -
Effective tax rate of
41.5% to45.0% ; - Annualized diluted share count of 19.1 million; and
- Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.
_________________________
(1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
Non-GAAP Financial Measures
This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.
Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.
Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.
Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.
The Company prepares its financial statements using
Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP) |
||||||||||||||||
|
Three
|
|
Three Months Ended |
|
Twelve Months Ended |
|||||||||||
|
September
|
|
December
|
|
December
|
|
December
|
|
December
|
|||||||
Net earnings attributable to USANA (GAAP) |
$ |
10,607 |
|
$ |
4,454 |
|
|
$ |
16,766 |
|
$ |
42,030 |
|
|
$ |
63,788 |
|
|
|
|
|
|
|
|
|
|
|||||||
Earnings per common share - Diluted (GAAP) |
$ |
0.56 |
|
$ |
0.23 |
|
|
$ |
0.87 |
|
$ |
2.19 |
|
|
$ |
3.30 |
Weighted Average common shares outstanding - Diluted |
|
19,083 |
|
|
19,104 |
|
|
|
19,253 |
|
|
19,162 |
|
|
|
19,345 |
|
|
|
|
|
|
|
|
|
|
|||||||
Adjustment to net earnings: |
|
|
|
|
|
|
|
|
|
|||||||
Transaction costs - Hiya |
$ |
- |
|
$ |
8,243 |
|
|
$ |
- |
|
$ |
8,243 |
|
|
$ |
- |
Integration and transition costs - Hiya |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
Inventory step-up - Hiya |
|
- |
|
|
38 |
|
|
|
- |
|
|
38 |
|
|
|
- |
Amortization of intangible assets - Hiya |
|
- |
|
|
294 |
|
|
|
- |
|
|
294 |
|
|
|
- |
Adjustments to net earnings attributable to non-controlling interest |
|
- |
|
|
(70 |
) |
|
|
- |
|
|
(70 |
) |
|
|
- |
Income tax effect of adjustments to net earnings |
|
- |
|
|
(823 |
) |
|
|
- |
|
|
(823 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|||||||
Adjusted net earnings attributable to USANA |
$ |
10,607 |
|
$ |
12,136 |
|
|
$ |
16,766 |
|
$ |
49,712 |
|
|
$ |
63,788 |
|
|
|
|
|
|
|
|
|
|
|||||||
Adjusted earnings per common share - Diluted |
$ |
0.56 |
|
$ |
0.64 |
|
|
$ |
0.87 |
|
$ |
2.59 |
|
|
$ |
3.30 |
Weighted average common shares outstanding - Diluted |
|
19,083 |
|
|
19,104 |
|
|
|
19,253 |
|
|
19,162 |
|
|
|
19,345 |
Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP) |
|||||||||||||||||||
|
Three
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||
|
September
|
|
December
|
|
December
|
|
December
|
|
December
|
||||||||||
Net earnings attributable to USANA (GAAP) |
$ |
10,607 |
|
|
$ |
4,454 |
|
|
$ |
16,766 |
|
|
$ |
42,030 |
|
|
$ |
63,788 |
|
Net earnings attributable to non-controlling interest |
|
- |
|
|
|
30 |
|
|
|
- |
|
|
|
30 |
|
|
|
- |
|
Net earnings |
$ |
10,607 |
|
|
$ |
4,484 |
|
|
$ |
16,766 |
|
|
$ |
42,060 |
|
|
$ |
63,788 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjustments: |
|
|
|
|
|
|
|
|
|
||||||||||
Income taxes |
|
8,001 |
|
|
|
5,945 |
|
|
|
9,845 |
|
|
|
34,291 |
|
|
|
38,665 |
|
Interest (income) expense |
|
(3,093 |
) |
|
|
(2,609 |
) |
|
|
(2,760 |
) |
|
|
(11,038 |
) |
|
|
(9,375 |
) |
Depreciation and amortization |
|
5,559 |
|
|
|
5,590 |
|
|
|
4,871 |
|
|
|
21,935 |
|
|
|
20,395 |
|
Amortization of intangible assets - Hiya |
|
- |
|
|
|
294 |
|
|
|
- |
|
|
|
294 |
|
|
|
- |
|
Earnings before interest, taxes, depreciation, and amortization (EBITDA) |
|
21,074 |
|
|
|
13,704 |
|
|
|
28,722 |
|
|
|
87,542 |
|
|
|
113,473 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Add EBITDA adjustments: |
|
|
|
|
|
|
|
|
|
||||||||||
Non-cash share-based compensation |
|
3,542 |
|
|
|
3,613 |
|
|
|
3,643 |
|
|
|
14,558 |
|
|
|
14,595 |
|
Transaction costs - Hiya |
|
- |
|
|
|
8,243 |
|
|
|
- |
|
|
|
8,243 |
|
|
|
- |
|
Integration and transition costs - Hiya |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Inventory step-up - Hiya |
|
- |
|
|
|
38 |
|
|
|
- |
|
|
|
38 |
|
|
|
- |
|
Consolidated adjusted EBITDA |
|
24,616 |
|
|
|
25,598 |
|
|
|
32,365 |
|
|
|
110,381 |
|
|
|
128,068 |
|
Less: Adjusted EBITDA attributable to non-controlling interest |
|
- |
|
|
|
(101 |
) |
|
|
- |
|
|
|
(101 |
) |
|
|
- |
|
Adjusted EBITDA attributable to USANA |
$ |
24,616 |
|
|
$ |
25,497 |
|
|
$ |
32,365 |
|
|
$ |
110,280 |
|
|
$ |
128,068 |
|
Management Commentary Document and Conference Call
For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, February 26, 2025 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “expect,” “enhance,” “drive,” “anticipate,” “intend,” “improve,” “promote,” “should,” “believe,” “continue,” “plan,” “goal,” “opportunity,” “estimate,” “predict,” “may,” “will,” “could,” and “would,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements that Hiya is a growing, highly cash-generative brand that is positioned to deliver long-term sustainable growth over the next several years and strong growth in 2025; statements about the Company’s long-term growth; and the statements under the sub-heading “Fiscal Year 2025 Outlook.” Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk that our Associate compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in
About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout
USANA Health Sciences, Inc. | ||||||||||||||
Consolidated Statements of Operations | ||||||||||||||
(In thousands, except per share data) | ||||||||||||||
(Unaudited) | ||||||||||||||
Quarter Ended | Twelve Months Ended | |||||||||||||
28-Dec-24 | 30-Dec-23 | 28-Dec-24 | 30-Dec-23 | |||||||||||
Net sales | $ |
213,613 |
|
$ |
221,083 |
$ |
854,503 |
|
$ |
921,010 |
||||
Cost of sales |
|
38,553 |
|
|
42,319 |
|
161,212 |
|
|
176,693 |
||||
Gross profit |
|
175,060 |
|
|
178,764 |
|
693,291 |
|
|
744,317 |
||||
Operating expenses: | ||||||||||||||
Associate incentives |
|
93,502 |
|
|
95,881 |
|
363,699 |
|
|
394,257 |
||||
Selling, general and administrative |
|
73,348 |
|
|
58,664 |
|
263,268 |
|
|
256,989 |
||||
Earnings from operations |
|
8,210 |
|
|
24,219 |
|
66,324 |
|
|
93,071 |
||||
Other income (expense), net |
|
2,219 |
|
|
2,392 |
|
10,027 |
|
|
9,382 |
||||
Earnings before income taxes |
|
10,429 |
|
|
26,611 |
|
76,351 |
|
|
102,453 |
||||
Income taxes |
|
5,945 |
|
|
9,845 |
|
34,291 |
|
|
38,665 |
||||
Net earnings | $ |
4,484 |
|
$ |
16,766 |
$ |
42,060 |
|
$ |
63,788 |
||||
Less (net earnings) loss attributable to non-controlling interest |
|
(30 |
) |
|
- |
|
(30 |
) |
|
- |
||||
Net earnings attributable to USANA | $ |
4,454 |
|
$ |
16,766 |
$ |
42,030 |
|
$ |
63,788 |
||||
Earnings per share - diluted | $ |
0.23 |
|
$ |
0.87 |
$ |
2.19 |
|
$ |
3.30 |
||||
Weighted average shares outstanding - diluted |
|
19,104 |
|
|
19,253 |
|
19,162 |
|
|
19,345 |
USANA Health Sciences, Inc. | ||||||
Consolidated Balance Sheets | ||||||
(In thousands) | ||||||
(Unaudited) | ||||||
As of | As of | |||||
28-Dec-24 | 30-Dec-23 | |||||
ASSETS | ||||||
Current Assets | ||||||
Cash and cash equivalents | $ |
181,768 |
$ |
330,420 |
||
Inventories |
|
69,735 |
|
61,454 |
||
Prepaid expenses and other current assets |
|
27,684 |
|
25,872 |
||
Total current assets |
|
279,187 |
|
417,746 |
||
Property and equipment, net |
|
94,565 |
|
99,814 |
||
Goodwill |
|
144,168 |
|
17,102 |
||
Intangible assets, net |
|
151,823 |
|
29,919 |
||
Deferred tax assets |
|
19,644 |
|
13,284 |
||
Other assets* |
|
58,806 |
|
54,892 |
||
Total assets | $ |
748,193 |
$ |
632,757 |
||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Current Liabilities | ||||||
Accounts payable | $ |
11,984 |
$ |
10,070 |
||
Line of credit - short term |
|
23,000 |
|
786 |
||
Other current liabilities |
|
104,641 |
|
107,989 |
||
Total current liabilities |
|
139,625 |
|
118,845 |
||
Deferred tax liabilities |
|
4,073 |
|
4,552 |
||
Other long-term liabilities |
|
18,163 |
|
12,158 |
||
Non-controlling interest |
|
54,223 |
|
- |
||
Stockholders' equity |
|
532,109 |
|
497,202 |
||
Total liabilities and stockholders' equity | $ |
748,193 |
$ |
632,757 |
*Includes noncurrent inventories of |
USANA Health Sciences, Inc. | ||||||||||||||||||||||||||
Sales by Region | ||||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||
(Unaudited) | ||||||||||||||||||||||||||
Quarter Ended | ||||||||||||||||||||||||||
December 28, 2024 | December 30, 2023 | Change from prior year | Currency impact on sales |
% change excluding currency impact |
||||||||||||||||||||||
$ |
112,587 |
52.7 |
% |
$ |
115,921 |
52.4 |
% |
$ |
(3,334 |
) |
(2.9 |
%) |
$ |
353 |
|
(3.2 |
%) |
|||||||||
|
38,061 |
17.8 |
% |
|
39,116 |
17.7 |
% |
|
(1,055 |
) |
(2.7 |
%) |
|
562 |
|
(4.1 |
%) |
|||||||||
|
16,542 |
7.8 |
% |
|
22,065 |
10.0 |
% |
|
(5,523 |
) |
(25.0 |
%) |
|
(883 |
) |
(21.0 |
%) |
|||||||||
Asia Pacific Total |
|
167,190 |
78.3 |
% |
|
177,102 |
80.1 |
% |
|
(9,912 |
) |
(5.6 |
%) |
|
32 |
|
(5.6 |
%) |
||||||||
|
44,453 |
20.8 |
% |
|
43,981 |
19.9 |
% |
|
472 |
|
1.1 |
% |
|
(1,061 |
) |
3.5 |
% |
|||||||||
Total USANA |
|
211,643 |
99.1 |
% |
|
221,083 |
100.0 |
% |
|
(9,440 |
) |
(4.3 |
%) |
|
(1,029 |
) |
(3.8 |
%) |
||||||||
Hiya |
|
1,970 |
0.9 |
% |
|
1,970 |
|
|
- |
|
||||||||||||||||
Consolidated Total | $ |
213,613 |
100.0 |
% |
$ |
221,083 |
100.0 |
% |
$ |
(7,470 |
) |
(3.4 |
%) |
$ |
(1,029 |
) |
(2.9 |
%) |
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION (unaudited) |
||||||||||
Active Associates by Region(1) | ||||||||||
(Unaudited) | ||||||||||
As of | ||||||||||
December 28, 2024 | December 30, 2023 | |||||||||
67,000 |
35.4 |
% |
70,000 |
35.0 |
% |
|||||
51,000 |
27.0 |
% |
52,000 |
26.0 |
% |
|||||
26,000 |
13.8 |
% |
32,000 |
16.0 |
% |
|||||
Asia Pacific Total | 144,000 |
76.2 |
% |
154,000 |
77.0 |
% |
||||
45,000 |
23.8 |
% |
46,000 |
23.0 |
% |
|||||
189,000 |
100.0 |
% |
200,000 |
100.0 |
% |
|||||
Active Preferred Customers by Region (2) | ||||||||||
(Unaudited) | ||||||||||
As of | ||||||||||
December 28, 2024 | December 30, 2023 | |||||||||
179,000 |
67.6 |
% |
185,000 |
65.4 |
% |
|||||
26,000 |
9.8 |
% |
28,000 |
9.9 |
% |
|||||
12,000 |
4.5 |
% |
16,000 |
5.6 |
% |
|||||
Asia Pacific Total | 217,000 |
81.9 |
% |
229,000 |
80.9 |
% |
||||
48,000 |
18.1 |
% |
54,000 |
19.1 |
% |
|||||
265,000 |
100.0 |
% |
283,000 |
100.0 |
% |
(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.
(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225808997/en/
Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7201
investor.relations@usanainc.com
Media contact:
Sarah Searle
(801) 954-7626
media@usanainc.com
Source: USANA Health Sciences, Inc.